New MRI-Guided radiation aims to tame recurrent prostate cancer with fewer side effects
NCT ID NCT07142967
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This trial tests a precise form of radiation therapy guided by MRI and PSMA/PET imaging for men whose prostate cancer has returned after prior radiation. The goal is to see whether this approach can effectively treat the recurrent tumor while reducing serious urinary and bowel side effects. Participants will receive five focused radiation sessions along with hormone therapy for 4–6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT)
- What this could lead to
- If successful, this approach could offer a safer way to treat prostate cancer that has come back after initial radiation, potentially reducing severe urinary and bowel side effects.
- What could go wrong
- This is a small, early-phase study with only 28 participants, so results may not apply to everyone. The treatment still carries risks of serious side effects, and it is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAPROSTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States